

**SAUDI CHEMICAL HOLDING COMPANY
AND ITS SUBSIDIARIES**

(A SAUDI JOINT STOCK COMPANY)

**INTERIM CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS AND
INDEPENDENT AUDITOR'S REVIEW REPORT**

**FOR THE THREE-MONTHS PERIOD ENDED 31
MARCH 2026**

Saudi Chemical Holding Company and Its Subsidiaries
(A Saudi Joint Stock Company)

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

31 March 2026

<i>INDEX</i>	<i>PAGE</i>
Independent Auditor's Review Report	1
Interim Condensed Consolidated Statement of Financial Position	2
Interim Condensed Consolidated Statement of Comprehensive Income	3
Interim Condensed Consolidated Statement of Changes in Equity	4
Interim Condensed Consolidated Statement of Cash Flows	5
Notes to the Interim Condensed Consolidated Financial Statements	6-17



Shape the future
with confidence

ERNST & YOUNG PROFESSIONAL SERVICES (PROFESSIONAL LLC)
PAID-UP CAPITAL (٥,500,000 - FIVE MILLION FIVE HUNDRED THOUSAND SAUDI RIYAL)

Head Office
Financial Boulevard 3126, Al Aqeeq Dist. 6717, Riyadh 13519
KAFD 1.11 B, South Tower, 8th Floor
P.O. Box 2732, Riyadh 11461
Kingdom of Saudi Arabia

C.R. No.: 1010383821
Unified No.: 7000117205

Tel: +966 11 215 9898
+966 11 273 4740
Fax: +966 11 273 4730

ey.ksa@sa.ey.com
ey.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS TO THE SHAREHOLDERS OF SAUDI CHEMICAL HOLDING COMPANY (A SAUDI JOINT STOCK COMPANY)

Introduction

We have reviewed the accompanying interim condensed consolidated statement of financial position of Saudi Chemical Holding Company - a Saudi Joint Stock Company (the "Company") and its subsidiaries (collectively referred to as the "Group") as at 31 March 2026, and the related interim condensed consolidated statements of comprehensive income, changes in equity and cash flows for the three-month period then ended, and explanatory notes. Management is responsible for the preparation and presentation of these interim condensed consolidated financial statements in accordance with International Accounting Standard 34, "Interim Financial Reporting" ("IAS 34") as endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these interim condensed consolidated financial statements based on our review.

Scope of Review

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" as endorsed in the Kingdom of Saudi Arabia. A review of interim financial statement consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34 as endorsed in the Kingdom of Saudi Arabia.

for Ernst & Young Professional Services

Hesham A. Alatiqi
Certified Public Accountant
License No. 523



Riyadh: 27 Thul-Qi'dah 1447H
(14 May 2026)

Saudi Chemical Holding Company and Its Subsidiaries
(A Saudi Joint Stock Company)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 31 March 2026

	Notes	31 March 2026 S\$ '000 (Unaudited)	31 December 2025 S\$ '000 (Audited)
ASSETS			
NON- CURRENT ASSETS			
Property, plant and equipment	3.1	604,092	609,346
Capital work in progress	3.2	497,196	497,145
Intangible assets and goodwill	3.3	619,533	620,317
Right of use assets		44,792	47,377
Derivative financial instruments	4	792	329
TOTAL NON- CURRENT ASSETS		1,766,405	1,774,514
CURRENT ASSETS			
Inventories		1,357,260	1,543,038
Trade receivables	5	2,509,431	2,631,474
Prepayments and other current assets		258,627	161,541
Amounts due from a related party	6	6,942	6,942
Cash and cash equivalents		210,626	117,501
TOTAL CURRENT ASSETS		4,342,886	4,460,496
TOTAL ASSETS		6,109,291	6,235,010
LIABILITIES AND EQUITY			
EQUITY			
Share capital	7	843,200	843,200
Statutory reserve		341,868	341,868
General reserve		340,000	340,000
Retained earnings		944,993	857,786
<i>Equity attributable to equity holders of the parent</i>		2,470,061	2,382,854
Non-controlling interests		14,989	14,257
TOTAL EQUITY		2,485,050	2,397,111
LIABILITIES			
NON-CURRENT LIABILITIES			
Long term Islamic loans – non-current	8.3	176,471	194,118
Saudi Industrial Development Fund's financing – non-current	8.1	233,151	251,492
Government grant		877	1,255
Lease liabilities – non-current		23,633	31,296
Employee's defined benefit liabilities		77,294	75,501
TOTAL NON-CURRENT LIABILITIES		511,426	553,662
CURRENT LIABILITIES			
Saudi industrial Development Fund's financing – current	8.1	56,047	50,935
Government grant		1,506	1,506
Lease liabilities – current		22,968	15,952
Long-term Islamic loans – current	8.3	134,902	134,902
Short-term Islamic loans	8.2	519,286	504,454
Trade payable		2,125,742	2,307,005
Accrued expenses and other liabilities		154,722	182,215
Zakat and income tax payable	9	84,382	74,008
Dividends payable		13,260	13,260
TOTAL CURRENT LIABILITIES		3,112,815	3,284,237
TOTAL LIABILITIES		3,624,241	3,837,899
TOTAL EQUITY AND LIABILITIES		6,109,291	6,235,010

Samah Hassan
Group CFO

Eng. Abdulsalam Alghamdi
Group CEO

Fawaz Al-Fawaz
Chairman of Board of Directors

The attached notes 1 to 17 form an integral part of these interim condensed consolidated financial statements.


Saudi Chemical Holding Company and Its Subsidiaries
(A Saudi Joint Stock Company)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(UNAUDITED)


For the three-month period ended 31 March 2026

	Notes	For the three-month period ended 31 March	
		2026 S'000	2025 S'000
Revenues		1,726,730	1,643,717
Cost of revenues		(1,523,048)	(1,430,446)
Gross profit		203,682	213,271
Selling and distribution expenses		(41,248)	(41,274)
General and administrative expenses		(37,376)	(37,655)
Expected credit loss on trade receivables	5	(12,567)	(15,621)
Operating profit		112,491	118,721
Financial cost		(17,404)	(23,385)
Other income, net		2,838	198
Foreign currency exchange (losses) gain		(74)	54
Revaluation gain / (loss) on derivative financial instruments	4	462	(1,604)
Profit before zakat and income tax		98,313	93,984
Zakat and income tax expenses	9	(10,374)	(10,870)
Net profit for the period		87,939	83,114
Other comprehensive income for the period		-	-
Total comprehensive income for the period		87,939	83,114
Net profit for the period attributable to:			
Equity holders of the parent		87,207	82,328
Non-controlling interests		732	786
		87,939	83,114
Basic and diluted earnings per share attributable to equity holders of the parent (S)	10	0.10	0.10

Sameh Hassan
Group CFO



Eng. Abdulsalam Alghamdi
Group CEO



Fawaz Al-Fawaz
Chairman of Board of Directors



The attached notes 1 to 17 form an integral part of these interim condensed consolidated financial statements.

Saudi Chemical Holding Company and Its Subsidiaries
(A Saudi Joint Stock Company)


INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
For the three-month period ended 31 March 2026

	<i>Attributable to the equity holders of the parent</i>				<i>Total</i> س.م '000	<i>Non-controlling interests</i> س.م '000	<i>Total equity</i> س.م '000
	<i>Share capital</i> س.م '000	<i>Statutory reserve</i> س.م '000	<i>General reserves</i> س.م '000	<i>Retained earnings</i> س.م '000			
At 31 December 2024 (Audited)	843,200	341,868	340,000	565,870	2,090,938	11,577	2,102,515
Net profit for the period	-	-	-	82,328	82,328	786	83,114
Other comprehensive income for the period	-	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	82,328	82,328	786	83,114
At 31 March 2025 (Unaudited)	843,200	341,868	340,000	648,198	2,173,266	12,363	2,185,629
At 31 December 2025 (Audited)	843,200	341,868	340,000	857,786	2,382,854	14,257	2,397,111
Net profit for the period	-	-	-	87,207	87,207	732	87,939
Other comprehensive income for the period	-	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	87,207	87,207	732	87,939
At 31 March 2026 (Unaudited)	843,200	341,868	340,000	944,993	2,470,061	14,989	2,485,050


Samih Hassan
Group CFO



Eng. Abdulsalam Alghamdi
Group CEO



Fawaz Al-Fawaz
Chairman of Board of Directors



The attached notes 1 to 17 form an integral part of these interim condensed consolidated financial statements.

Saudi Chemical Holding Company and Its Subsidiaries
(A Saudi Joint Stock Company)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED)

For the three-month period ended 31 March 2026

	Note	For the Three-month period ended 31 March	
		2026 S'000	2025 S'000
Operating activities			
Profit before zakat and income tax		98,313	93,984
Adjustments for:			
Amortization of intangible assets	3.3	2,420	2,308
Depreciation of property, plant and equipment	3.1	12,519	14,493
Depreciation of right-of-use assets		1,548	1,488
Property, plant and equipment written off		-	738
Provision for inventories		-	2,301
Provision for advance to supplier		1,800	-
Expected credit loss on trade receivables	5	12,567	15,621
Provision for employees' defined benefit obligation		4,489	4,899
Revaluation (gain) loss on derivative financial instruments	4	(462)	1,604
Finance costs		17,404	23,385
		<u>150,598</u>	<u>160,821</u>
Working capital changes:			
Inventories		185,778	(137,237)
Trade receivables		109,476	46,238
Prepayments and other current assets		(98,886)	8,893
Trade payables		(181,263)	(129,659)
Accrued expenses and other liabilities		(27,493)	(42,957)
Amounts due to related parties		-	(119)
		<u>138,210</u>	<u>(94,020)</u>
Cash generated from (used in) operations		138,210	(94,020)
Employees defined benefit obligation paid		(975)	(1,440)
Finance costs paid		(15,918)	(20,920)
		<u>121,317</u>	<u>(116,380)</u>
Net cash flows generated from (used in) operating activities		121,317	(116,380)
Investing activities			
Purchase of property, plant and equipment and capital work in progress		(7,800)	(11,132)
Purchase of intangible assets	3.3	(1,152)	(120)
		<u>(8,952)</u>	<u>(11,252)</u>
Net cash flows used in investing activities		(8,952)	(11,252)
Financing activities			
Payment of principal portion of lease liabilities		(1,425)	(3,316)
Short-term Islamic loans – net		14,832	196,675
Repayment of long-term Islamic loans		(17,647)	-
Repayment of Saudi Industrial Development Fund's financing		(15,000)	-
		<u>(19,240)</u>	<u>193,359</u>
Net cash flows (used in) generated from financing activities		(19,240)	193,359
Net increase in cash and cash equivalents		93,125	65,727
Cash and cash equivalents at the beginning of the period		117,501	129,525
		<u>210,626</u>	<u>195,252</u>
Cash and cash equivalent at the end of the period		210,626	195,252

SIGNIFICANT NON-CASH TRANSACTIONS:

Transfer from capital work in progress to property, plant, and equipment & intangible asset	3.2	1,666	16,501
---	-----	-------	--------

Samah Hassan
Group CFO

Eng. Abdulsalam Alghamdi
Group CEO

Fawaz Al-Fawaz
Chairman of Board of Directors

The attached notes 1 to 17 form an integral part of these interim condensed consolidated financial statements.

Saudi Chemical Holding Company and Its Subsidiaries (A Saudi Joint Stock Company)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

As at 31 March 2026

1 CORPORATE INFORMATION AND ACTIVITIES

Saudi Chemical Holding Company (the "Company") is a Saudi Joint Stock Company registered in Riyadh, Kingdom of Saudi Arabia, under commercial registration number 1010006161 and unified identification number 7006356716 dated 12 Safar 1392H (corresponding to 28 March 1972). The registered office of the Company is: P.O. Box 2665 Riyadh 11461, Kingdom of Saudi Arabia. The Company is listed in Tadawul stock exchange.

The Company and its subsidiaries (collectively referred to as the "Group") are principally engaged in:

- Managing the subsidiaries or participating in the management of other investees and providing the required support for these entities and real estate ownership.
- Manufacturing and selling of explosives and their derivatives for civil or military uses and providing technical support services in explosions.
- Manufacturing, wholesale and retail trading in medicines, medical materials and syrups, pharmaceutical preparations, medical and surgical tools and equipment, supplies of hospitals and medical centers and its related spare parts and food items; and
- Manufacture of ammonium nitrate.

These interim condensed consolidated financial statements include the financial statements of the Company and its following subsidiaries:

<i>Subsidiary</i>	<i>Country of incorporation</i>	<i>Main Activity</i>	<i>Legal and beneficial ownership interest %</i>	
			<i>31 March 2026</i>	<i>31 December 2025</i>
Saudi International Trading Company ("SITCO Pharma")	Kingdom of Saudi Arabia	Distribution of Medicines	99%	99%
Suez International Nitrate Company ("SINCO")	Arab Republic of Egypt	Production of Ammonium Nitrate	100%	100%
Chemical Company for Commercial Investment Limited ("CCCIL")	Kingdom of Saudi Arabia	Wholesale and retail trade in medicines, cosmetics, perfumes, beauty soaps, medical tools, and other supplies	100%	100%
AJA Pharmaceuticals Industries Company Limited ("AJA Pharma Company")	Kingdom of Saudi Arabia	Manufacturing pharmaceutical products, packaging and storing of medicines, and other medical products.	100%	100%
Saudi Chemical Company Limited ("SCCL")	Kingdom of Saudi Arabia	Establishment, manufacturing & Ownership of explosive Factories	100%	100%
Saha Al-Hayya Holding Company ("Sihavita")	Kingdom of Saudi Arabia	Managing, investing the funds, owning real estate, providing loans and guarantees and financing, and owning industrial rights of subsidiaries of the holding company.	100%	100%
Zand Al-Teenemiya Holding Company ("XND")	Kingdom of Saudi Arabia	Managing, investing the funds, owning real estate, providing loans and guarantees and financing, and owning industrial rights of subsidiaries of the holding company.	100%	100%

Saudi Chemical Holding Company and Its Subsidiaries (A Saudi Joint Stock Company)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (Continued)

As at 31 March 2026

2 BASIS OF PREPARATION

These interim condensed consolidated financial statements have been prepared in accordance with International Accounting Standard, Interim Financial Reporting” (“IAS 34”) as endorsed in Kingdom of Saudi Arabia and other standards and pronouncements that are endorsed by the Saudi Organization for Chartered and Professional Accountants (“SOCPA”).

The interim condensed consolidated financial statements do not include all the information and disclosures required for a complete set of annual consolidated financial statements and therefore, should be read in conjunction with the Group’s annual consolidated financial statements for the year ended 31 December 2025.

An interim period is considered an integral part of the whole fiscal year, however, the results of operations for the interim period may not be a fair indication of the results of the full year operations.

Basis of measurement and functional currency

The interim condensed consolidated financial statements have been prepared on a historical cost basis using the accrual basis of accounting and the going concern assumption concept, except for the valuation of employees defined benefits liability which is measured at present value and derivative financial instruments which are measured at Fair Value Through Profit or Loss (FVTPL).

These interim condensed consolidated financial statements are presented in thousands of Saudi Riyals (“ﷲ”) unless stated otherwise. ﷲ is also the functional currency of the Group. ﷲ is the presentation currency of the Company and all its subsidiaries except for SINCO which uses United States Dollar (“USD”) as its presentation currency.

2.1 SUMMARY OF MATERIAL ACCOUNTING POLICY INFORMATION

The accounting policies used in the preparation of these interim condensed consolidated financial statements are consistent with those used in the preparation of the Group's annual financial statements for the year ended 31 December 2025, except for the application of new accounting policies below effective from 1 January 2026.

The Group has not early adopted any new standards, interpretations or amendments that have been issued but are not yet effective.

Many of the amendments and interpretations are effective for the first time in 2026, but do not have any material impact on the Group's interim condensed consolidated financial statements. The nature and impact of these changes are disclosed below.

Classification and Measurement of Financial Instruments – Amendments to IFRS 9 and IFRS 7

In May 2024, the IASB issued Amendments to IFRS 9 and IFRS 7, Amendments to the Classification and Measurement of Financial Instruments (the Amendments). The Amendments include:

- Clarifications of the requirements for recognition and derecognition of financial assets and financial liabilities.
In particular, a financial liability is derecognised on the ‘settlement date’ and an accounting policy choice is introduced (if specific conditions are met) to derecognise financial liabilities settled using an electronic payment system before the settlement date.
- Additional guidance on how the contractual cash flows for financial assets with environmental, social and corporate governance (ESG) and similar features should be assessed
- Clarifications on what constitute ‘non-recourse features’ and what are the characteristics of contractually linked instruments.
- The introduction of disclosures for financial instruments with contingent features and additional disclosure requirements for equity instruments classified at fair value through other comprehensive income (OCI).

The amendments did not have impact on the Group’s interim condensed consolidated financial statements.

Saudi Chemical Holding Company and its Subsidiaries (A Saudi Joint Stock Company)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

As at 31 March 2026

2 BASIS OF PREPARATION (continued)

2.1 SUMMARY OF MATERIAL ACCOUNTING POLICY INFORMATION (CONTINUED)

Annual Improvements to IFRS accounting Standards – Volume 11

In July 2024, the IASB issued nine narrow scope amendments as part of its periodic maintenance of IFRS accounting standards. The amendments include clarifications, simplifications, corrections or changes to improve consistency in IFRS 1 First-time Adoption of International Financial Reporting Standards, IFRS 7 Financial instruments: Disclosure and its accompanying Guidance on implementing IFRS 7, IFRS 9 Financial Instruments, IFRS 10 Consolidated Financial Statements and IAS 7 Statements of Cash Flows.

The amendments are effective for annual reporting periods beginning on or after 1 January 2026. When applying the amendments, an entity cannot restate comparative information.

The amendments did not have impact on the Group's interim condensed consolidated financial statements.

Contracts Referencing Nature -dependent Electricity – Amendments to IFRS 9 and IFRS 7

In December 2024, the IASB issued Amendments to IFRS 9 and IFRS 7 - Contracts Referencing Nature-dependent Electricity. The amendments apply only to contracts that reference nature-dependent electricity, and they:

- Clarify the application of the 'own-use' requirements for in-scope contracts.
- Amend the designation requirements for a hedged item in a cash flow hedging relationship for in -scope contracts
- Add new disclosure requirements to enable investors to understand the effect of these contracts on a company's financial performance and cash flows.

The amendments did not have impact on the Group's interim condensed consolidated financial statements.

New and amended standards and interpretations not yet effective

The new amended, issued standards and interpretations, which are not effective yet have not been adopted early by the Group and will be adopted on their effective date as applicable. The adoption of these standards and interpretations is not expected to have any material impact on the Group on the effective date, except IFRS 18, which the Group is currently evaluating the impact of its adoption on the financial statements.

Standard, Amendment or Interpretation

- IFRS 18: Presentation and Disclosure in Financial Statements – Replaces IAS (1) Presentation of Financial Statements.
- IFRS (19) - Subsidiaries without Public Accountability: Disclosures
- IAS (21) The Effects of Changes in Foreign Exchange Rates - Translation to a Hyperinflationary Presentation Currency
- Amendments to IFRS (10) and IAS (28): Sale or Contribution of Assets between an Investor and its Associate or Joint Venture

Effective date

1 January 2027
1 January 2027
1 January 2027

The effective date of this amendment is postponed indefinitely.

2.2 ACCOUNTING ESTIMATES AND ASSUMPTIONS AND JUDGMENTS

The preparation of the Group's interim condensed consolidated financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures. Actual results may differ from these estimates. The significant judgments reached by the management when preparing these condensed consolidated interim financial statements in applying the Group's accounting policies and the main sources of estimation uncertainty, including risk management policies are the same applied in the annual financial statements for the year ended on 31 December 2025.

Recent geopolitical developments in the Middle East

The Group continues to monitor the regional geopolitical developments and their potential impact, while supply chain has been impacted in terms of cost and availability, these developments have not had a material impact on Group's financial statements for the period ended 31 March 2026. However, given the evolving nature of the situation, the potential impact on the Group's business and financial performance will continue to be assessed on future reporting dates as further escalation or prolonged continuation of the conflict could potentially affect its business.

Saudi Chemical Holding Company and its Subsidiaries
(A Saudi Joint Stock Company)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED) (CONTINUED)

As at 31 March 2026

3 PROPERTY, PLANT AND EQUIPMENT, CAPITAL WORK IN PROGRESS AND INTANGIBLE ASSETS AND GOODWILL

3.1 PROPERTY, PLANT AND EQUIPMENT

The following is a summary of the movement in property, plant and equipment:

	<i>31 March 2026 S\$ '000 (Unaudited)</i>	<i>31 December 2025 S\$ '000 (Audited)</i>
<i>Cost</i>		
Balance at the beginning of the period/year	1,235,269	1,195,469
Additions	6,083	18,254
Disposals	-	(1,650)
Transfers from capital work in progress	1,182	23,196
Balance at the end of the period/year	<u>1,242,534</u>	<u>1,235,269</u>
<i>Accumulated depreciation</i>		
Balance at the beginning of the period/year	625,923	577,378
Charge for the period/year	12,519	49,201
Disposals	-	(656)
Balance at the end of the period/year	<u>638,442</u>	<u>625,923</u>
<i>Net book value</i>	<u>604,092</u>	<u>609,346</u>

3.2 CAPITAL WORK IN PROGRESS

The following is a summary of the movement in Capital work in progress:

	<i>31 March 2026 S\$ '000 (Unaudited)</i>	<i>31 December 2025 S\$ '000 (Audited)</i>
Balance at the beginning of the period/year	497,145	499,111
Additions	1,717	22,339
Transfer to property, plant and equipment	(1,182)	(23,196)
Transfers to intangible assets	(484)	(1,109)
Balance at the end of the period/year	<u>497,196</u>	<u>497,145</u>

Refer to Note 12.2 the capital commitments related to these projects.

Capital work-in-progress mainly represents costs incurred in establishing the Group's new explosives factory in Riyadh, in addition to other projects carried out to comply with security regulations. The plant is expected to commence production during the year ending 31 December 2026.

Saudi Chemical Holding Company and its Subsidiaries
(A Saudi Joint Stock Company)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED) (CONTINUED)

As at 31 March 2026

3 PROPERTY, PLANT AND EQUIPMENT, CAPITAL WORK IN PROGRESS AND INTANGIBLE ASSETS AND GOODWILL (continued)

3.3 INTANGIBLE ASSETS AND GOODWILL

The following is a summary of the movement in Intangible assets:

	<i>New brand key money</i> S\$ '000	<i>Computer software</i> S\$ '000	<i>Goodwill</i> S\$ '000	<i>Other intangible assets</i> S\$ '000	<i>Total</i> S\$ '000
<i>Cost</i>					
As at 31 December 2025 (audited)	12,500	53,235	469,807	138,820	674,362
Additions	-	1,152	-	-	1,152
Transfer from capital work in progress	-	484	-	-	484
As at 31 March 2026 (unaudited)	12,500	54,871	469,807	138,820	675,998
<i>Amortization and impairment</i>					
As at 31 December 2025 (audited)	12,500	27,200	-	14,345	54,045
Amortization	-	1,032	-	1,388	2,420
As at 31 March 2026 (unaudited)	12,500	28,232	-	15,733	56,465
Net book value					
As at 31 March 2026 (unaudited)	-	26,639	469,807	123,087	619,533
	<i>New brand key money</i> S\$ '000	<i>Computer software</i> S\$ '000	<i>Goodwill</i> S\$ '000	<i>Other intangible assets</i> S\$ '000	<i>Total</i> S\$ '000
<i>Cost</i>					
As at 1 January 2025	12,500	49,516	469,807	138,820	670,643
Additions	-	2,610	-	-	2,610
Transfer	-	1,109	-	-	1,109
As at 31 December 2025	12,500	53,235	469,807	138,820	674,362
<i>Amortization and impairment</i>					
As at 1 January 2025	12,500	23,073	-	8,792	44,365
Amortization	-	4,127	-	5,553	9,680
As at 31 December 2025	12,500	27,200	-	14,345	54,045
<i>Net Book Value</i>					
As at 31 December 2025	-	26,035	469,807	124,475	620,317

4 DERIVATIVE FINANCIAL INSTRUMENTS

Derivative financial instruments designated at fair value through profit or loss represent a portfolio of profit rate swaps having maturity dates range from 2027 to 2028 with three-month variable interest rate and prevailing interest rates between the Saudi banks ("SIBOR"). These derivatives do not meet the criteria for hedge accounting. The nominal value of the contracts as at 31 March 2026 was S\$ 700 million (31 December 2025: S\$ 700 million) and the fair value of derivatives amounted to S\$ 0.792 million (31 December 2025: S\$ 0.329 million). The change in the fair value of derivatives represents a gain of S\$ 0.462 million for the three-month period ended 31 March 2026 (31 March 2025: loss of S\$ 1.604 million).

Saudi Chemical Holding Company and its Subsidiaries
(A Saudi Joint Stock Company)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED) (CONTINUED)

As at 31 March 2026

5 TRADE RECEIVABLES

	<i>31 March 2026 S\$ '000 (Unaudited)</i>	<i>31 December 2025 S\$ '000 (Audited)</i>
Trade receivables	2,803,340	2,912,816
Allowance for expected credit loss	(293,909)	(281,342)
Total	2,509,431	2,631,474

Trade receivables from Saudi government institutions represent 62% of the total trade receivables as of 31 March 2026 (31 December 2025: 64 % of the total trade receivable). These institutions have a strong credit rating in the Saudi market.

6 TRANSACTIONS WITH RELATED PARTIES

Related parties represent shareholders, directors, key management personnel of the Group, and entities controlled, jointly controlled, or significantly influenced by such parties. As at period and year end, all transactions between subsidiaries were eliminated.

6.1 COMPENSATION AND BENEFITS OF KEY EXECUTIVES

The following represent the compensation of the executives:

	<i>31 March 2026 S\$ '000 (unaudited)</i>	<i>31 March 2025 S\$ '000 (unaudited)</i>
Expenses and remuneration of the Board of Directors	1,350	1,350
Short-term benefits and remuneration	7,889	11,074
Post-employment benefits	96	217

6.2 BALANCES OF RELATED PARTIES

The following table shows the total amount of transactions made with related parties during the Three-month period ended on 31 March 2026 and 31 March 2025, in addition to the balances with related parties as at 31 March 2026 and 31 December 2025:

<i>Name of related party</i>	<i>Relationship</i>	<i>Nature of transaction</i>	<i>For the three-month period ended 31 March</i>		<i>Balance as at</i>	
			<i>2026 S\$ '000 (unaudited)</i>	<i>2025 S\$ '000 (unaudited)</i>	<i>31 March 2026 S\$ '000 (unaudited)</i>	<i>31 December 2025 S\$ '000 (audited)</i>

Amounts from a related party

<i>Care Supply Chain for Logistics Services *</i>	<i>Joint venture</i>	<i>Expense paid on behalf</i>	-	119	6,942	6,942
---	----------------------	-------------------------------	---	-----	-------	-------

* Care Supply Chain for Logistic Services Company Ltd. (the "Joint Venture" or "CSC") is a joint venture in which the Group owns a common control and partners' resolutions are adopted unanimously as per the Joint Venture's Articles of Association, with an ownership interest of 50%. The Joint Venture has been incorporated as per Saudi Regulations and registered in Riyadh under commercial registration number 1010846387 on 17 Jumada Al-Ula 1444H (11 December 2022) with a share capital at an amount of S\$ 500 divided into 500 shares with S\$ 1000 each. The objective of the Joint Venture is to provide transportation services, loading, unloading, warehousing and distribution. The Group's share in the joint venture is accounted for under equity method.

Saudi Chemical Holding Company and Its Subsidiaries

(A Saudi Joint Stock Company)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (Continued)

As at 31 March 2026

7 SHARE CAPITAL

As at 31 March 2026, the share capital of the Company consists of 843,200,000 shares with nominal value of ~~ﷲ~~ 1 per share aggregating to ~~ﷲ~~ 843,200,000 (31 December 2025: 843,200,000 shares with nominal value of ~~ﷲ~~ 1 per share aggregating to ~~ﷲ~~ 843,200,000).

8 LOANS AND BORROWINGS

8.1 SAUDI INDUSTRIAL DEVELOPMENT FUND'S FINANCING

The long-term loans were obtained by two subsidiaries of the Group from Saudi Industrial Development Fund ("SIDF") to meet the Group's capital expenditure. The first loan was obtained by AJA Pharmaceuticals Industries Limited ("AJA Pharma") during 2016 and amounted to ~~ﷲ~~ 157.5 million, of which the full amount of the facility has been utilized as at 31 March 2026 (31 December 2025: ~~ﷲ~~ 157.5 million). The second loan was obtained by Saudi Chemical Company Limited ("SCCL") during 2020 and amounted to ~~ﷲ~~ 229 million, of which the full amount of the facility has been utilized as at 31 March 2026 (31 December 2025: ~~ﷲ~~ 229 million).

On 18 Jumada al-Ula 1447H corresponding to 6 November 2025, SCCL obtained an additional financing facility of ~~ﷲ~~ 50 million to support working capital requirements. Administrative fees of ~~ﷲ~~ 2.5 million were deducted upfront and are amortized over the term of the facility. The additional financing is repayable through a single payment after two years from the date of the agreement on 27 Jumada al-Alkhirah 1449H corresponding to 06 November 2027.

The loan to AJA Pharma is repayable in sixteen semi-annual installments starting from 15 Shawwal 1444 H (corresponding to 5 May 2024), while the loan to SCCL is repayable in fourteen semi-annual installments starting from 15 Rabi Al-Thani 1444 H (corresponding to 9 November 2022).

The loans from SIDF carried fixed commission charges of ~~ﷲ~~ 28.9 million, which have been paid upfront by the Group at the beginning of the loan term. The commission charges are being amortized over the terms of the loans. As at 31 March 2026, the unamortized balance amounted to ~~ﷲ~~ 8.059 million (31 December 2025: ~~ﷲ~~ 9.034 million).

The amortization of such qualified charges along with other finance costs of the loan are capitalized as part of the carrying value of the property, plant and equipment (during the construction period).

The agreements are secured promissory notes, and pledge of the subsidiaries' property, plant and equipment. The subsidiaries are required to comply with certain covenants under the loan facilities obtained.

The following represents a summary of information about the Saudi Industrial Development Fund's:

	<i>31 March 2026 ﷲ '000 (Unaudited)</i>	<i>31 December 2025 ﷲ '000 (Audited)</i>
Loans from Saudi Industrial Development Fund	300,500	315,500
Less: Unamortized processing fees	(8,059)	(9,034)
Present value adjustment	(3,243)	(4,039)
	289,198	302,427
Current	56,047	50,935
Non-current	233,151	251,492
	289,198	302,427

Movement in unamortized transaction costs are as follows:

	<i>31 March 2026 ﷲ '000 (Unaudited)</i>	<i>31 December 2025 ﷲ '000 (Audited)</i>
Balance at the beginning of the period/year	9,034	9,685
Additions during the year	-	2,500
Amortized during the period/year	(975)	(3,151)
Balance at the end of the period/year	8,059	9,034

Saudi Chemical Holding Company and its Subsidiaries (A Saudi Joint Stock Company)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

As at 31 March 2026

8 LOANS AND BORROWINGS (continued)

8.2 SHORT-TERM ISLAMIC LOANS

The Group is using Islamic financing to finance its business operations. These facilities bear finance cost at SIBOR plus prevailing market rates. The facilities are secured by promissory notes. The facilities agreement includes covenants requiring the maintenance of certain levels of financial ratios.

8.3 LONG TERM ISLAMIC LOANS

In June 2022, the Group acquired a long-term Islamic loan from a local bank in the amount of **ﷲ** 300 million to finance the construction of the subsidiary's factory. The loan is subject to the prevailing interest rates between the Saudi banks (SIBOR) plus a profit margin. The loan is repayable in 6 years in quarterly installments after a grace period three years.

Also, during June 2022, the Group acquired a long-term Islamic loan from a local bank in the amount of **ﷲ** 140 million to finance its acquisition of a pharmaceutical product. The loan is subject to the prevailing interest rates between the Saudi banks (SAIBOR) plus a profit margin. The loan is repayable in equal 6 semi-annual installments with the last installment payable in December 2026 after a grace period of two year. The facility agreement includes covenants requiring the maintenance of certain levels of financial ratios.

9 ZAKAT AND INCOME TAX

Movement in Zakat and income Tax provision during the period/year

	<i>31 March 2026 ﷲ '000 (Unaudited)</i>	<i>31 December 2025 ﷲ '000 (Audited)</i>
As at the beginning period/year	74,008	63,820
Charged during the period/year	10,374	47,566
Paid during the period/year	-	(37,378)
As at the end of the period/year	84,382	74,008

Zakat and income tax provisions of **ﷲ** 10.37 million were recognized by the Group during the three-month period ended 31 March 2026 (31 March 2025: **ﷲ** 10.87 million). The Company, SITCO Pharma, CCCIL, AJA Pharma and SCCL have filed their zakat declarations and obtained zakat certificates for the years up to 2019.

The Group obtained the approval from Zakat, Tax and Customs Authority ("ZATCA") to submit consolidated zakat returns for the Company and the following subsidiaries: SCCL, AJA Pharma, and CCCIL starting from the year 2020. In addition, SITCO Pharma submits a separate zakat return. The group has submitted its consolidated zakat returns for the years 2020 to 2025. No assessment has been raised by ZATCA for the years from 2020 to 2025 yet.

SITCO Pharma has filed its zakat declarations for the years up to 2025. During the period ended 31 March 2026, SITCO obtained the final zakat assessments for years 2020, 2021 and 2022 from ZATCA. No differences were produced from the final zakat assessment. No assessment has been raised by ZATCA for the years from 2023 to 2025 yet.

INCOME TAX

The income tax expense payable by a foreign subsidiary, in accordance with the prevailing tax regulations in its country, for the period ended 31 March 2026 amounted to **ﷲ** 0.291 million (31 March 2025: **ﷲ** 1.2 million).

Saudi Chemical Holding Company and its Subsidiaries
(A Saudi Joint Stock Company)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED) (CONTINUED)

As at 31 March 2026

10 BASIC AND DILUTED EARNING PER SHARE

Earnings per share is computed using net profit for the period attributable to Shareholders of the Company based on the weighted average number of shares outstanding for the period ended 31 March 2026 and 2025 by 843,200,000 shares.

The diluted earnings per share are the same as the basic earnings per share as the Group does not have any dilutive instruments in issue.

The following table reflects the income for the year attributable to equity holders of the parent and share data used in the basic and diluted EPS computations:

	<i>31 March 2026 ﷲ '000 (Unaudited)</i>	<i>31 March 2025 ﷲ '000 (Unaudited)</i>
Income for the year attributable to equity holders of the parent	<u>87,207</u>	<u>82,328</u>
Weighted average number of ordinary shares	<u>843,200,000</u>	<u>843,200,000</u>
Basic and diluted earnings per share attributable to equity holders of the parent (ﷲ)	<u>0.10</u>	<u>0.10</u>

11 FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES

11.1 Fair value Hierarchy

Assets and liabilities measured at fair value in the interim condensed consolidated statement of financial position are grouped into three levels of fair value hierarchy. This grouping is determined based on the lowest level of significant inputs used in fair value measurement, as follows:

Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

All the financial assets and liabilities of the Company are carried at amortized cost except for derivative financial instruments which are classified as fair value through profit or loss.

11.2 Carrying amount vs Fair value

	<i>Fair value measurement hierarchy</i>	<i>31 March 2026 (Unaudited)</i>		<i>31 December 2025 (Audited)</i>	
		<i>Carrying value</i>	<i>Fair value</i>	<i>Carrying value</i>	<i>Fair value</i>
Derivative financial instruments	Level 2	792	792	329	329

The derivative financial instrument is carried at fair value using valuation techniques, which employ the use of market observable inputs.

The Group considers that the carrying amount of trade receivables, amount due from a related party, other assets, cash and cash equivalents, Saudi Industrial Development Fund's financing, long-term Islamic loans, lease liabilities, short-term Islamic loans, trade payables, dividends payable, accrued expenses and other liabilities are a reasonable approximation of their fair value.

Saudi Chemical Holding Company and its Subsidiaries
(A Saudi Joint Stock Company)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED) (CONTINUED)

As at 31 March 2026

12 CONTINGENT LIABILITIES AND CAPITAL COMMITMENTS

12.1 CONTINGENT LIABILITIES

- a) As at 31 March 2026, the Group had outstanding letters of guarantee amounting to **ﷲ** 314.6 million (31 December 2025: **ﷲ** 337.6 million), issued in the normal course of business of the Group. Moreover, as at 31 March 2026, the Group had outstanding letters of credit amounting to **ﷲ** 42.81 million (31 December 2025: **ﷲ** 54.1 million).
- b) The Group has contingent liabilities from time to time relating to certain disputed matters, including claims from and against contractors, litigation and arbitration proceedings involving a variety of cases. These contingent liabilities arose in the normal course of business. The management believes and with the consulting of its legal consultant that no additional significant obligations are expected to be incurred from these potential claims.

12.2 COMMERCIAL AND CAPITAL COMMITMENTS

Capital commitments outstanding as at 31 March 2026, in respect of capital work in progress projects of **ﷲ** 41.76 million (31 December 2025: **ﷲ** 36.3 million).

13 SEGMENTAL INFORMATION

For management purposes, the Group consists of business units according to the products and services it provides. The Group's operations are principally in the explosives, medicines and medical supplies and production of ammonium nitrate. Except for the information related to the production of ammonium nitrate segment that is located in the Arab Republic of Egypt, all other information is related to the business segments in the Kingdom of Saudi Arabia. All inter-company transactions within the appropriately reported segments have been eliminated.

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated on the basis of the statement of comprehensive income and is measured on a consistent basis based on profit or loss in the consolidated financial statements.

	<i>Explosives</i> ﷲ '000	<i>Medicine and medical supplies</i> ﷲ '000	<i>Production of ammonium nitrate</i> ﷲ '000	<i>Head office</i> ﷲ '000	<i>Eliminations/ Adjustments</i> ﷲ '000	<i>Total</i> ﷲ '000
<i>As at 31 March 2026</i> <i>(Unaudited)</i>						
Segment assets	1,053,488	4,729,243	82,700	3,200,157	(2,956,297)	6,109,291
Segment liabilities	702,433	3,134,888	51,709	730,094	(994,883)	3,624,241
<i>As at 31 December</i> <i>2025 (Audited)</i>						
Segment assets	1,026,636	4,811,562	86,423	3,054,359	(2,743,970)	6,235,010
Segment liabilities	670,760	3,309,391	55,496	671,503	(867,251)	3,837,899

Saudi Chemical Holding Company and its Subsidiaries
(A Saudi Joint Stock Company)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED) (CONTINUED)

As at 31 March 2026

13 SEGMENTAL INFORMATION (continued)

	<i>Explosives</i> S'000	<i>Medicine and medical supplies</i> S'000	<i>Production of ammonium nitrate</i> S'000	<i>Head office</i> S'000	<i>Eliminations</i> S'000	<i>Total</i> S'000
<i>For the three-month period ended 31 March 2026 (Unaudited)</i>						
Revenues	88,758	1,635,041	2,931	-	-	1,726,730
Intersegment revenue	-	42,408	10,804	-	(53,212)	-
<i>Net revenues</i>	88,758	1,677,449	13,735	-	(53,212)	1,726,730
Segment comprehensive income (loss)	(4,823)	91,574	65	87,208	(86,085)	87,939

	<i>Explosives</i> S'000	<i>Medicine and medical supplies</i> S'000	<i>Production of ammonium nitrate</i> S'000	<i>Head office</i> S'000	<i>Eliminations</i> S'000	<i>Total</i> S'000
<i>For the three-month period ended 31 March 2025 (Unaudited)</i>						
Revenues	82,390	1,548,342	12,985	-	-	1,643,717
Intersegment revenue	-	30,186	11,813	-	(41,999)	-
<i>Net revenues</i>	82,390	1,578,528	24,798	-	(41,999)	1,643,717
Segment comprehensive income (loss)	(975)	84,936	2,882	82,330	(86,059)	83,114

14 DIVIDENDS

During the period, on 23 Ramadhan 1447H (corresponding to 12 March 2026), the Board of Directors recommended to distribute cash dividends of S'0.10 per share amounting to S'84.320 million for fiscal year 2025 subject to General Assembly approval.

15 COMPARATIVE FIGURES

Certain comparative figures for the previous year have been reclassified to conform to the current year's presentation.

	<i>2025 As previously Reported</i> S'000	<i>Reclassification</i> S'000	<i>2025 Amount as per FS</i> S'000
Cost of sales	1,423,742	6,704	1,430,446
Selling and Marketing expenses	47,978	(6,704)	41,274

Saudi Chemical Holding Company and its Subsidiaries
(A Saudi Joint Stock Company)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED) (CONTINUED)

As at 31 March 2026

16 SUBSEQUENT EVENTS

The management of the Group believes that no significant events have occurred subsequent to the period end that may require adjustment to or disclosure other than those disclosed elsewhere in these interim condensed consolidated financial statements.

17 APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

These interim condensed consolidated financial statements have been approved by the Board of Directors of the Company on 27 Thul-Qi'dah 1447 H (corresponding to 14 May 2026).